文献速递免疫规划传染病防控与疫情报告

mRNA疫苗对COVID-19住院的保护效果持续24周

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2021-08-27

在18个州21家医院开展的成人研究显示,完成两剂Pfizer-BioNTech或Moderna mRNA疫苗接种后,对COVID-19相关住院的疫苗有效性(VE)在24周内持续存在。全程监测期VE为86%(95%CI 82%-88%),无免疫抑制条件成人为90%(95%CI 87%-92%),接种后2-12周与13-24周VE无显著变化。

要点

  • 完成两剂mRNA疫苗接种对COVID-19住院的VE在24周内持续,无显著下降。
  • 无免疫抑制条件成人VE更高(90%),提示该人群获益更明确。
  • 所有符合条件者均应接种COVID-19疫苗以降低住院风险。

核心结论

  • mRNA疫苗对COVID-19相关住院的保护效果在接种第二剂后24周内持续存在。
  • 包括重症COVID-19高风险人群在内,疫苗有效性均得以维持。
  • 随着新变异株出现,需持续监测疫苗有效性。

研究设计与样本

  • 在18个州21家医院开展的评估,纳入3,089名≥18岁住院成人。
  • 其中COVID-19病例患者1,194例,非COVID-19对照患者1,895例。
  • 中位年龄59岁,48.7%为女性,21.1%有免疫抑制条件。

主要发现

  • 全程监测期VE总体为86%(95%CI 82%-88%)。
  • 无免疫抑制条件成人VE为90%(95%CI 87%-92%)。
  • 接种后2-12周VE为86%(95%CI 82%-90%),13-24周为84%(95%CI 77%-90%),两期间无显著变化(p=0.854)。
  • 454例病例标本测序中,B.1.1.7(Alpha)占53.3%(242例),B.1.617.2(Delta)占16.3%(74例)。

关键数值与推荐

  • 全程接种定义为在症状出现前≥14天已接种第二剂Pfizer-BioNTech或Moderna mRNA COVID-19疫苗。
  • 第二剂接种后中位间隔65天(范围14-166天)。
  • 病例患者中141例(11.8%)全程接种,对照中988例(52.1%)全程接种。

临床怎么用

  • 应向所有符合条件者提供COVID-19疫苗接种,以降低住院风险。
  • 对无免疫抑制条件成人,mRNA疫苗对住院的保护效果在24周内维持较高水平。
  • 需持续监测新变异株对疫苗有效性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1-4) measured shortly after vaccination; longer follow-up is needed to assess durability of protection. In an evaluation at 21 hospitals in 18 states, the duration of mRNA vaccine (Pfizer-BioNTech or Moderna) effectiveness (VE) against COVID-19-associated hospitalizations was assessed among adults aged ≥18 years. Among 3,089 hospitalized adults (including 1,194 COVID-19 case-patients and 1,895 non-COVID-19 control-patients), the median age was 59 years, 48.7% were female, and 21.1% had an immunocompromising condition. Overall, 141 (11.8%) case-patients and 988 (52.1%) controls were fully vaccinated (defined as receipt of the second dose of Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines ≥14 days before illness onset), with a median interval of 65 days (range = 14-166 days) after receipt of second dose. VE against COVID-19-associated hospitalization during the full surveillance period was 86% (95% confidence interval [CI] = 82%-88%) overall and 90% (95% CI = 87%-92%) among adults without immunocompromising conditions. VE against COVID-19- associated hospitalization was 86% (95% CI = 82%-90%) 2-12 weeks and 84% (95% CI = 77%-90%) 13-24 weeks from receipt of the second vaccine dose, with no significant change between these periods (p = 0.854). Whole genome sequencing of 454 case-patient specimens found that 242 (53.3%) belonged to the B.1.1.7 (Alpha) lineage and 74 (16.3%) to the B.1.617.2 (Delta) lineage. Effectiveness of mRNA vaccines against COVID-19-associated hospitalization was sustained over a 24-week period, including among groups at higher risk for severe COVID-19; ongoing monitoring is needed as new SARS-CoV-2 variants emerge. To reduce their risk for hospitalization, all eligible persons should be offered COVID-19 vaccination.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Tenforde MW, Self WH, Naioti EA, et al. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34437524. doi:10.15585/mmwr.mm7034e2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。